Inivata Ltd.
Industry
- Biotechnology
- Pharmacogenetics-Pharmacogenomics
- In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Chemistry, Immunoassay
Latest on Inivata Ltd.
Inivata has moved one step closer to the full commercialization of its RaDaR assay, which can detect 48 subvariants of tumor DNA, with the publication of clinical validation data from its LIONESS s
Cambridge, UK-based Inivata has announced a collaboration with Princess Margaret Cancer Center to run two trials of its its InVisionFirst – Lung and RaDaR liquid biopsy tests. The Accelerating Lung
IV BioHoldings launched three liquid biopsy start-ups aimed at early detection and treatment of cancer and one focusing on metabolic disease: LiquidLung, HepGene and Mammogen. Incorporated in December
In May, there were two prominent acquisitions that centered on liquid biopsy technology. Labcorp agreed to pay $150m in cash for Myriad Genetics, Inc. ’s autoimmune business; while NeoGenomics, Inc.